The extracellular matrix (ECM) is a key acellular structure in constant remodeling to provide tissue cohesion and rigidity. Deregulation of the balance between matrix deposition, degradation, and crosslinking results in fibrosis. Bone marrow fibrosis (BMF) is associated with several malignant and nonmalignant pathologies severely affecting blood cell production. BMF results from abnormal deposition of collagen fibers and enhanced lysyl oxidase-mediated ECM crosslinking within the marrow, thereby increasing marrow stiffness. Bone marrow stiffness has been recently recognized as an important regulator of blood cell development, notably by modifying the fate and differentiation process of hematopoietic or mesenchymal stem cells. This review surveys the different components of the ECM and their influence on stem cell development, with a focus on the impact of the ECM composition and stiffness on the megakaryocytic lineage in health and disease.
| C OM P OSIT I ON OF T HE BON E M AR R OW E XTR A CEL LU L A R M A TR I X (E CM )
The bone marrow (BM) ECM is a noncellular structure that provides physical support for tissue integrity, elasticity, and hematopoesis. [1] [2] [3] The ECM is vital in normal hematopoiesis and plays a role in pathological states. It is comprised of various matrix proteins, such as collagens, laminin, fibronectin, and fibrinogen, as well as various soluble proteins, such as cytokines, chemokines, and secreted enzymes. 1, 4, 5 Of the different ECM structural proteins, the main ones are collagens, which include fibrillary collagen (collagens I, II, III, V, and XI) and nonfibrillary collagen, with the former providing stiffness to the ECM. 1 Cellular adhesion to collagen has been found to promote bone marrow cells and megakaryocyte (MK) expansion. [6] [7] [8] Similar to collagen, fibronectin is important for cellular interactions with the ECM, and plays a role in adhesion, migration, growth, and differentiation. [9] [10] [11] [12] The ECM also contains proteoglycans with attached glycosaminoglycan (GAG) side chains. These GAGs bind to and sequester growth factors in the ECM and may act as a reservoir of these cell-impacting proteins. 1, 3 Heparan sulfate is a GAG involved in mobilization of hematopoietic stem cells (HSCs), 13 and the GAG hyaluronic acid is important for normal hematopoiesis. [14] [15] [16] Other ECM proteins, such as fibrillin-1, tenascin-C, agrin, thrombospondin, and matrilin-4 are important for HSC proliferation and survival during homeostatic and stress conditions, as well as regulation of angiogenesis. [17] [18] [19] [20] [21] The ECM is in constant remodeling. Among ECM modifying proteins are matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMPs), plasmin, and lysyl oxidase (LOX). MMPs are a family of zincdependent endopeptidases that are the main enzymes responsible for ECM breakdown, while TIMPs counteract this breakdown by inhibiting
MMPs. 22 Dysregulation of these counteracting proteins affects the ECM in some pathological states, such as multiple myeloma (MM) and primary myelofibrosis (PMF). 5, 23 TIMP-3, not only inhibits MMPs in the BM, but also plays a role in HSC expansion, differentiation, and trafficking. 24, 25 Plasmin is a protein activated by urokinase plasminogen activator (uPA), which has been found to be expressed in mouse hematopoietic stem cells and progenitors and by human BM stromal cells. [26] [27] [28] Plasmin degrades fibrin, fibronectin and laminin, while activating MMPs. 27 Other components of hemostasis are also found in the ECM, such as plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (tPA), and fibrinogen. In the bone marrow, these factors are important for hematopoietic regeneration. 29, 30 PAI-1 inhibits the degradation of plasmin during hemostasis, and it has also been reported to be expressed in MKs. 31 Altered PAI-1 level is associated the balance between matrix secretion and deposition, cross-linking and degradation, tissue stiffness may vary under physiological or pathophysiological conditions.
| B ONE M A RR OW E CM STI F F NE SS: M E A SU RE M EN T A N D NA TU R A L C ONTR I BU TOR S
Several ECM components in the BM contribute to the stiffness of the tissue. This property is typically assessed by methods such as rheometry 36 and atomic force microscopy (AFM). 37 Rheometry involves measuring the viscoelastic properties of a substance by looking at the relationship between deformations and stresses to calculate Young's modulus, a measurement for stiffness. 38 The limitation of rheometry is that it looks at the BM as a whole at the macroscopic level and cannot detect regional or cellular heterogeneity of stiffness. 38 Other studies have used a micropipette aspiration method to measure stiffness by placing a glass capillary micropipette next to the tissue and applying vacuum pressure to measure the aspirated length, which is then used to calculate soft tissue stiffness. 39 This method may be used in BM to find regional differences in stiffness; however, it faces the same limitations of rheometry in that it does not measure stiffness at the cell level.
One way to measure ECM stiffness in BM at the cellular level involves AFM as it can provide a spatial resolution of almost 1 nm and can be used in solution and in living cells. 40 AFM can also be used to measure stiffness of collagens and other ECM components. 41 Another method for measuring ECM stiffness at the cellular level is optical tweezers active microrheology. 42 The stiffness of the ECM is heterogeneous throughout the BM, 38 likely due to heterogeneous distribution of ECM components. Collagens are important contributors to ECM stiffness; Types I, II, and III are the most abundant collagens in the ECM. 43 For example, type IV and type I collagen are found mainly near the endosteal surface in the BM along with fibronectin, and fibronectin is also found in MKs and in central marrow. 44, 45 Type IV collagen is detected in the vasculature of the BM, while type I collagen is not normally found in those areas. 45 Other BM ECM components, such as fibrinogen, plasmin, PAI-1
and vitronectin, and thrombospondin-2 (TSP-2) have also been
reported to affect MK function and proplatelet production. 34, 63, 64 MKs adhere to fibrinogen via a IIb b 3 . 60 Fibrinogen is mainly found in the vascular sinusoids in the BM, and upon binding to it, MKs have increased proplatelet formation. 34 PAI-1 inhibited MK adhesion to vitronectin, but its effect was reverse in the presence of tPA or uPA. 65 Thrombospondin-2 (TSP-2) is a matricellular protein that is expressed by MKs but not platelets and has been found to reduce proplatelet formation and MK differentiation in vitro.
66
Glycosaminoglycans (GAGs), other important components of the ECM, play an important role in MK development. 67 The GAG hyaluronic acid appears to be an important inhibitor of platelet production as depolymerazation of hyaluran is necessary for thrombopoesis; MKs with hyaluronidase-2 deficiency are less mature and make fewer proplatelets than hyaluronidase-2 containing MKs. 68 However, in normal MKs, high molecular weight hyaluronic acid does not effect MKs and, therefore, may make a good ex vivo 3D scaffold. 69 This is in contrast to the GAG dermatan sulfate, which increases proplatelet production in thrombopoetin (TPO)-stimulated MKs, compared to MKs cultured without this GAG.
70
LOX is a nonstructural component of the ECM that affects MK proliferation, adhesion and function. LOX is expressed in immature normal MKs and downregulated as MKs mature. 53 As mentioned above, the stiffness of the ECM is increased by LOX via cross-linking of collagen fibers, 35 and LOX expression is upregulated in MKs of mouse or human primary myelofibrosis. LOX can also potentiate platelet derived growth factor (PDGF)-mediated MK proliferation by oxidizing and activating the PDGF receptor. 53, 71 Another role of LOX is the activation of the collagen receptor a 2 b 1 on platelets, which leads to increased adhesion to collagen. 72 Reducing the stiffness of the ECM by inhibiting LOX crosslinking of collagen in mouse bone marrow, increased platelet level, supporting the notion that a less stiff matrix favors platelet biogenesis. 57 LOX may affect MK development by mechanisms other than catalytic oxidation of receptors or the ECM. LOX is secreted as a 50-kDa pro-enzyme that is cleaved by BMP-1 (also expressed by MKs) to release the mature LOX enzyme and the 18-kDa propeptide (LOX-PP) that can enter cells. 73, 74 LOX-PP decreases MK polyploidy, possibly by decreasing the expression of cell cycle regulators. 75 Stiffness also plays a role in MK function and development. MKs cultured in 3D media that mimic BM ECM stiffness had higher ploidy levels than MKs cultured in liquid media. 76 MKs cultured inside a 3D methylcellulose (MC) hydrogel of medium rigidity (30-60 Pa) had higher ploidy, higher demarcation membrane development and more proplatelet formation than MKs cultured in 2D on top of the gel or in liquid culture 76 or in a 3D stiffer rigidity (300-600 Pa). 76 A separate study looked at MKs cultured on collagen-coated soft gels (300 Pa) or stiff gels (34 kPa) and found that MKs had higher ploidy on softer gels compared to stiffer gels, independent of the collagen concentration. 77 However, this effect was abolished when the MKs were treated with a nonmuscle myosin inhibitor. 77 Ex vivo studies show that MKs forms more proplatelets on low to medium stiffness silk films than on high stiffness silk films, regardless if the silk films were coated with type I or type IV collagen. 57, 78 Increased stiffness also led to increased b1 integrin activation and internalization in MKs. 57 Although some stiffness is needed for MK maturation, it appears that a stiff ECM is detrimental to MK development and proplatelet formation. ECM stiffness appears to control proplatelet formation via PI3K/Akt signaling pathways with decreased stiffness causing increased Akt phosphorylation while MKs had decreased proplatelet formation when treated with Akt inhibitor. 57 Figure 1 includes an illustrative summary of the main ECM components that have the potential to affect stiffness.
| Effect on blood stem cells and other bone marrow cells
The stiffness of the ECM is also important for HSC fate and differentiation. 62, [79] [80] [81] HSCs cultured on stiffer gels coated with fibronectin (mimicking the endosteal region of the BM) promoted the maintenance of myeloid progenitors, while laminin-coated gels promoted erythroid differentiation. 62 Laminin also increased the number of mature red blood cell (RBC) progenitors derived from human HSCs. 82 Further, culturing murine HSCs on three dimensional collagen matrices of different stiffness revealed that HSCs on stiffer matrices were more quiescent. 81 HSCs cultured on collagen gels showed increased viability when cultured on less stiff gels (44 Pa) than on stiffer gels (3.48 kPa). 83 Similarly, on collagen-coated stiff PA gels (136 kPa), HSCs showed decreased viability as the collagen concentration coating the gels was increased. 83 Culturing cord blood derived-CD341 HSCs on collagen gels led to decreased expansion but increased myeloid differentiation, compared to HSCs cultured in suspension. 84 In a gene-expression assay, several growth factors, chemokines and cytokines were upregulated in HSCs cultured on collagen gels compared to suspension culture, including interleukins 8, 6 and 1b, TNFa, CXCL2, and CCL2 which are involved in HSC proliferation and mobilization. 84 Similar to HSCs, human mesenchymal stem cells (MSCs) cultured on a type I collagencoated gel matrix show different phenotypes depending on the rigidity of the matrix. MSCs cultured on a softer matrix appear more neurogenic and express more neurogenic genes, and those cultured on more rigid surfaces exhibit an osteogenic phenotype. 79, 80 Fibronectin is another ECM component that is important for hem- increased BM recovery as well as augmented IL-1 and IL-6 production by HSC, which support hematopoiesis. 15 Heparan sulfate is another GAG that is important for hematopoiesis. 89 HSCs express Mac-1 (CD11b/CD18) and CD45 which mediate their adhesion to stromal heparan sulfate. BM and blood myeloid cell counts, while it decreased lymphocyte levels. 24 There was also increased HSC trafficking to the blood and spleen and late onset of fatal osteosclerosis in mice with upregulated TIMP-3, compared to matching controls. 24 The role of TIMP-3 in stimulating quiescent HSCs to proliferate appears to be independent of its MMPinhibiting activity and may be due to direct inhibition of angiopoietin-1 signaling, which mediates HSC quiescence. MKs express several integrins that sense the ECM around them and transduce signals to the cytoskeleton. 92, 93 Among these integrins, a 2 b 1 binds to type I collagen and decreases the production of proplatelets via the Rho/ROCK pathway. 94 Integrin a 2 b 1 also regulates the assembly of actin stress fibers in MKs, which mediate cell migration. 94 The
Rho/ROCK pathway regulates thrombopoesis by phosphorylating myosin light chain (MLC), which enhances actin-dependent myosin motor activity. 95 This regulation of thrombopoesis by the Rho/ROCK pathway may be important in controlling the timing of platelet formation by
MKs and preventing premature platelet formation while the MKs are still in the osteoblastic niche. 95 Indeed, patients with MYH9-related diseases (caused by mutations of the heavy chain of the nonmuscle myosin) present with macrothrombocytopenia that is thought to be due to premature proplatelet formation in the osteoblastic niche and impaired migration. [95] [96] [97] Given that type I collagen is found primarily in the osteoblastic niche and it is a significant contributor to ECM stiffness, it is logical that areas with large amounts of type I collagen have an unfavorable environment for platelet production. 8, 45, 46 FIG URE 1 Schematic illustration of megakaryocyte adhesion and fragmentation into platelets in the context of normal ECM stiffness. As depicted here, type I collagen is normally found near the periosteum, and other collagen types, such as collagen IV, Glycosaminoglycans (GAGS) and fibronectin are spread throughout the niche. Metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMP) are present to remodel and turnover the ECM. Collagen I is less stiff than collagen IV and the rigidity of both is impacted by the level of a cross-linking enzyme, lysyl oxidase (LOX) secreted from low ploidy megakaryocytes and osteoblasts. Other components of hemostasis found in the ECM (and not illustrated here), such as plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (tPA), and fibrinogen were too found to impact megakaryocyte development through mechanisms outlined in the review [Color figure can be viewed at wileyonlinelibrary.com] Extracellular calcium appears to be important in sensing the ECM in MKs, and MKs express mechano-sensitive ion channels that may play a role in platelet formation. One such mechano-sensitive ion channel is the transient receptor potential cation channel subfamily V member 4 (TRPV4). 57 This channel modulated the PI3K/Akt pathway in endothelial cells when physical stimuli were applied to their cell membrane. 105 In MKs, TRPV4 senses a soft ECM and increased intracellular calcium influx, leading to increased PI3K/Akt pathway activation and proplatelet formation. 57 Inhibition of TRPV4 in MKs adhered to type IV collagen decreased proplatelet formation. 57 Mice treated with the LOX inhibitor BAPN had reduced BM ECM stiffness, higher platelet counts and increased TRPV4 activation compared to control, which highlights the importance of this ion channel in sensing soft ECM and increasing platelet formation in vivo. 57 Another family of mechano-sensitive ion channels that may play a role in MK and platelet function is the Piezo family. Piezo1 and Piezo2
are mechanically activated ion channels that induce nonselective cationic currents in response to mechanical forces. [106] [107] [108] The Piezo proteins are activated by tension on the lipid membrane itself. 114 There may be a role for Piezo1 in cellular proliferation. In one study, epithelial cells had increased proliferation in response to mechanical stretching via activation of Piezo1 and subsequent calcium influx and ERK1/2 phosphorylation. 120 A recent study found that Piezo1 is expressed in human platelets and the Meg-01 MK cell line. 113 Extracellular calcium influx was induced in Meg-01 cells and platelets when exposed to fluid shear stress and when Meg-01 cells had their cell membranes mechanically deformed with a glass pipette. This influx was largely abolished by GsMTx-4, a Piezo1 inhibitor. 113 Interestingly, the addition of GsMTx-4 to whole blood for 30 seconds resulted in a reduction of thrombus formation under arterial flow on a collagen surface, though no difference was seen in platelet aggregation under low shear stress conditions.
112,113
The role of Piezo proteins in MK and proplatelet formation has not
been studied yet, though it seems to be a promising mechanosensors for ECM stiffness. Piezo1 and other mechanosensitive ion channels may play a role in MK function by affecting ion currents. 121 One such channel is a depolarization-gated potassium-selective (Kv) channel.
MKs express the a subunit (a pore forming subunit) of Kv, Kv1.3, which is encoded by the gene KCNA3. 122 Kv1.3 is important in early calcium influx in platelets, and Kv1.3 deficient mice had significantly higher platelet counts compared to WT, but no effects on megakaryopoeisis were seen. 122 Platelets and MKs also express calcium-activated potassium channels (KCa) which may help determine membrane potential and calcium influx. 121, 123 One such channel, KCa3.1, is important in stromal cell derived factor 1 (SDF-1) mediated platelet migration. 124 
| BON E M AR ROW PA TH OL OGY A S S OCI A TED WI TH A F I BR OTI C A N D S TI F FE R EC M
Given the importance of the ECM and cellular signaling evoked by it during maintenance of tissue homeostasis, it is not surprising that dysregulation of ECM components leads to tissue fibrosis that disrupts organ function and is an important cause of mortality and morbidity. infiltration, but without associated osteosclerosis. AIMF can also be secondary to an established disorder such as systemic lupus erythematosus (SLE). 133 However, although isolated case reports are regularly presented, it is still an underdiagnosed disorder. 134, 135 Infectious or inflammatory diseases may also be associated with BMF. This is the case for HIV or tuberculosis infection, visceral leishmaniasis, and pulmonary hypertension. In addition, disorders associated with vitamin D deficiency are also prone to development of BMF. Furthermore, exposure to toxins or radiations may lead to the development of BMF, as well as treatment with medications such as recombinant human IL-11 (rhIL-11), 136 or thrombopoietin receptor agonists. [137] [138] [139] [140] Several studies have tried to correlate the amount and type of fibrosis with disease prognosis, but the conclusions vary. The presence of reticulin fibers alone, characteristic of mild fibrosis, does not seem to correlate with disease severity or co-morbidities. Conversely, the presence of collagen fibers, representing higher grade of BMF, correlate with abnormal blood count and severity of the underlying disorders. 126, 130, 141 Nevertheless, in both cases, provided that adequate treatment exists for the disease, reticulin fibrosis and even collagen fibrosis can decrease or resolve. This is the case for AIMF and SLEassociated myelofibrosis treated with corticoids. 142 Increased reticulin fibrosis due to CML is also reversible with Imatinib therapy, but not with interferon. [143] [144] [145] In MPN patients, ruxolitonib or interferon treatment improves aspects of the pathology in some but not all patients. 146, 147 In cases where supportive care measures are ineffective, stem cell transplant eradicating the clone responsible for the neoplastic transformation has proven to be effective in resolving both collagen and reticulin fibrosis. 148, 149 In the BM, the main cells responsible for the increase in ECM are fibroblasts, which are usually found in close association with collagen fibers. 150, 151 Rather than an increase in number, it is most probably their activation or differentiation into matrix-producing cells which is responsible for augmented ECM deposition. 151, 152 Fibroblasts respond to a number of fibrogenic factors present in the diseased marrow.
Increases in cytokines such as interleukin (IL)-6, IL-12, IL-8, TNFa, IFNg, as well as profibrogenic growth factors such as TGFb, bFGF, VEGF, and TGFb1 have been implicated. 153 MKs are primarily responsible for the secretion of many of these profibrotic, angiogenic and pro-inflammatory factors stored in their alpha granules. [154] [155] [156] This has been well documented for PMF. In addition, nonmyeloproliferative fibrosis has also been linked to MK hyperplasias as is the case for AIMF. 135 Interestingly, the presence of MKs in the lungs was proposed to contribute to pulmonary fibrosis and pulmonary hypertension in systemic sclerosis. 157 In this context, it is worth noting that pulmonary hypertension is diagnosed in some patients with PMF and other MPNs, and has been associated with pulmonary EMH and fibrosis. 158 Yet, the degree of abundance and role of pulmonary MKs in health and disease, MPN included, require further study. In addition to MKs (and platelets), monocytes/macrophages could be alternative sources of fibrogenic growth factors. In PMF, monocytes are activated and overexpress IL-1
and TGFb, suggesting that they also contribute to the fibrotic process. 
| CON CL U SI ONS A N D FU T U RE DI R E CTI ON S
Deregulation of ECM remodeling with excess matrix deposition, increased matrix cross-linking activity and defective matrix degradation, leading to increased stiffness, are associated with bone marrow pathologies. Important efforts will be needed to identify the mechanotransduction pathways used by MKs and other BM cells to sense such changes in the ECM. This is especially important considering that pathologies associated with BMF are often linked to platelet production defects.
Not only platelet production but also platelet function may be affected by modifications of the mechanics of the vascular environment; as yet, unexplored area of investigation. The main function of platelets is to ensure hemostasis by forming a plug at the site of vascular injury that seals the breach and stops blood loss. 159 Platelets are also involved in arterial thrombosis, which occurs in diseased vessels presenting evolved atherosclerotic plaques. Upon erosion and rupture of such a plaque, platelets accumulate and form a thrombus that can become occlusive, resulting in life-threatening ischemic pathologies such as stroke and Figure 1 .
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myocardial infarction. 160 The stiffness of the exposed sub-endothelium in healthy vessels far differs from that found in stiffer atherosclerotic
vessels. An association between arterial stiffness and platelet activation has been reported. 161 This link was proposed to be indirect and appears to result from the reduced ability of atherosclerotic plaques to release normal levels of nitric oxide which maintain platelets in a resting state. 162 How stiff surfaces exposed after atherosclerotic plaque rupture modifies platelet function remains completely unknown and represents a very attractive research area which could provide some clues on why thrombus formation can become occlusive in diseased arteries as compared to healthy vessels. Recently, it was reported that platelets sense microenvironmental mechanical properties, including substrate stiffness, which results in biological signal responses. 163 Evidence was provided that modifying the substrate stiffness of a fibrin surface increases platelet adhesion and spreading. Future studies are required to determine whether these observations are relevant to hemostasis and/or arterial thrombosis. They could help to identify novel mechanosensitive receptors which might represent interesting novel antithrombotic targets. Such a mechano-sensitive receptor, Piezo1, has recently been reported to be expressed by platelets. Piezo-1 was shown to promote Ca 21 entry and could participate in thrombus formation under arterial shear stress. 113 Future studies of other platelet mechanosensors could provide insights on how these cells sense both matrix stiffness and shear forces in hemostasis and arterial thrombosis.
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